Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL14744733

CCc1cc(C(=O)O)c(=O)[nH]c1-c1ccc(N2CCC(CN)C2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 9/20 0.44
BPTF Q12830 1/20 0.38
KCNH2 Q12809 3/20 0.37
PIM1 P11309 1/20 0.37
CDK2 P24941 1/20 0.37
FLT4 P35916 1/20 0.37
CSNK2A1 P68400 1/20 0.37
PRKCD Q05655 1/20 0.37
PAK1 Q13153 1/20 0.37
MAPKAPK3 Q16644 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
DPP4 P27487 2/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
LPL P06858 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14758827 0.95 TOP1 (0.47) TOP1BPTFKCNH2PIM1CDK2
Trifluoroacetic Acid SCHEMBL16568721 0.89 KCNH2 (0.40) TOP1KCNH2DPP4DPP8DPP9
Trifluoroacetic Acid SCHEMBL14745223 0.89 DYRK1A (0.42) TOP1KCNH2PIM1MAPKAPK3PRKD2
SCHEMBL14744736 0.87 TOP1 (0.39) TOP1BPTFKCNH2PIM1PRKD2
Trifluoroacetic Acid SCHEMBL17595148 0.85 KCNH2 (0.53) KCNH2
Trifluoroacetic Acid SCHEMBL14741133 0.85 KCNH2 (0.53) KCNH2
Trifluoroacetic Acid SCHEMBL14745784 0.85 TOP1 (0.36) TOP1KCNH2DPP4DPP8DPP9
Trifluoroacetic Acid SCHEMBL14741239 0.85 KCNH2 (0.44) KCNH2CDK2DPP4DPP8DPP9
SCHEMBL14745306 0.85 KCNH2 (0.41) TOP1KCNH2PIM1PRKD2LIPG
SCHEMBL14741014 0.85 KCNH2 (0.41) TOP1KCNH2PIM1PRKD2LIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016039936-A2 MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 WO claimed
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-03-19 US claimed
EP-2750505-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP claimed
WO-2013033240-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO claimed
EP-2750505-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033240-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP TOP1 101/4885BPTF 1953/4885KCNH2 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.